DK3356529T3 - Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa - Google Patents

Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa Download PDF

Info

Publication number: DK3356529T3
Authority: DK; Denmark
Prior art keywords: lena; lpa; inhibiting; expression; compositions
Prior art date: 2015-10-01

Application number

DK16852695.2T

Other languages

English (en)

Inventor

Steven Kanner

David B Rozema

David L Lewis

Lauren J Almeida

Darren H Wakefield

Vladimir S Trubetskoy

Aaron Almeida

Tao Pei

Zhen Li

Stacey Melquist

Original Assignee

Arrowhead Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-10-01

Filing date

2016-09-30

Publication date

2021-11-08

2016-09-30 Application filed by Arrowhead Pharmaceuticals Inc filed Critical Arrowhead Pharmaceuticals Inc

2021-11-08 Application granted granted Critical

2021-11-08 Publication of DK3356529T3 publication Critical patent/DK3356529T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3517—Marker; Tag

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

DK16852695.2T 2015-10-01 2016-09-30 Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa DK3356529T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562235816P	2015-10-01	2015-10-01
US201662346304P	2016-06-06	2016-06-06
US201662383221P	2016-09-02	2016-09-02
PCT/US2016/054729 WO2017059223A2 (en)	2015-10-01	2016-09-30	Compositions and methods for inhibiting gene expression of lpa

Publications (1)

Publication Number	Publication Date
DK3356529T3 true DK3356529T3 (da)	2021-11-08

Family

ID=58424351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16852695.2T DK3356529T3 (da)	2015-10-01	2016-09-30	Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa

Country Status (36)

Country	Link
US (3)	US9932586B2 (da)
EP (2)	EP4029941A1 (da)
JP (4)	JP6991966B2 (da)
CN (1)	CN108368506A (da)
AU (2)	AU2016331084B2 (da)
BR (1)	BR112018006489A2 (da)
CA (1)	CA3000397A1 (da)
CL (1)	CL2018000803A1 (da)
CO (1)	CO2018003678A2 (da)
CR (1)	CR20180231A (da)
CY (1)	CY1125263T1 (da)
DK (1)	DK3356529T3 (da)
EA (1)	EA038478B1 (da)
ES (1)	ES2896298T3 (da)
HK (1)	HK1259063A1 (da)
HR (1)	HRP20211410T1 (da)
HU (1)	HUE055942T2 (da)
IL (3)	IL300438A (da)
JO (2)	JOP20210043A1 (da)
LT (1)	LT3356529T (da)
MA (1)	MA43347B1 (da)
MX (2)	MX2018003833A (da)
MY (1)	MY195796A (da)
PE (1)	PE20181139A1 (da)
PH (1)	PH12018500713A1 (da)
PL (1)	PL3356529T3 (da)
PT (1)	PT3356529T (da)
RS (1)	RS62523B1 (da)
SG (1)	SG10202008530TA (da)
SI (1)	SI3356529T1 (da)
TN (1)	TN2018000094A1 (da)
TW (2)	TWI784934B (da)
UA (1)	UA121998C2 (da)
UY (1)	UY36926A (da)
WO (1)	WO2017059223A2 (da)
ZA (1)	ZA202106265B (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7718133B2 (en)	2003-10-09	2010-05-18	3M Innovative Properties Company	Multilayer processing devices and methods
UY37146A (es) *	2016-03-07	2017-09-29	Arrowhead Pharmaceuticals Inc	Ligandos de direccionamiento para compuestos terapéuticos
UY37145A (es)	2016-09-02	2019-08-30	Arrowhead Pharmaceuticals Inc	Ligandos de direccionamiento
WO2018185241A1 (en)	2017-04-05	2018-10-11	Silence Therapeutics Gmbh	Products and compositions
BR112019023650A2 (pt) *	2017-07-06	2020-06-02	Arrowhead Pharmaceuticals, Inc.	Agentes rnai para inibir a expressão de alfa-enac e métodos de uso
EP3681516A4 (en) *	2017-09-11	2021-09-29	Arrowhead Pharmaceuticals, Inc.	RNA INTERFERENCE AGENTS AND COMPOSITIONS INTENDED TO INHIBIT APOLIPOPROTEIN C-III (APOC3) EXPRESSION
CN111343994B (zh) *	2017-09-14	2023-11-21	箭头药业股份有限公司	用于抑制血管生成素-样3 (ANGPTL3)的表达的RNAi剂和组合物以及使用方法
US11492624B2 (en) *	2017-10-17	2022-11-08	Arrowheads Pharmaceuticals, Inc.	RNAi agents and compositions for inhibiting expression of Asialoglycoprotein receptor 1
DK3710586T3 (da) *	2017-11-13	2023-01-23	Silence Therapeutics Gmbh	Nukleinsyrer til inhibering af ekspression af LPA i en celle
EP3483270A1 (en) *	2017-11-13	2019-05-15	Silence Therapeutics GmbH	Products and compositions
PE20211212A1 (es) *	2018-09-19	2021-07-05	Arrowhead Pharmaceuticals Inc	AGENTES DE ARNi PARA INHIBIR LA EXPRESION DE 17beta-HSD TIPO 13 (HSD17B13), COMPOSICIONES DE DICHOS AGENTES, Y METODOS DE USO
AU2019380628B2 (en)	2018-11-13	2024-10-31	Silence Therapeutics Gmbh	Nucleic acids for inhibiting expression of LPA in a cell
EP4073252A1 (en)	2019-12-09	2022-10-19	Amgen Inc.	Rnai constructs and methods for inhibiting lpa expression
KR20230043912A (ko) *	2020-08-05	2023-03-31	다이서나 파마수이티컬, 인크.	Lpa 발현을 저해하기 위한 조성물 및 방법
CN116490195A (zh) *	2020-10-16	2023-07-25	赛诺菲	用于抑制脂蛋白(a)的RNA组合物和方法
MX2023005198A (es)	2020-11-05	2023-05-16	Amgen Inc	Metodos para tratar la enfermedad cardiovascular aterosclerotica con constructos de iarn dirigidos a lpa.
WO2022121959A1 (zh) *	2020-12-09	2022-06-16	纳肽得有限公司	siRNA分子及其在治疗冠状动脉疾病中的应用
EP4237561A1 (en)	2020-12-23	2023-09-06	Argonaute Rna Limited	Treatment of cardiovascular disease
WO2022266316A1 (en)	2021-06-18	2022-12-22	Hongene Biotech Corporation	Functionalized n-acetylgalactosamine nucleosides
JP2024532271A (ja)	2021-08-30	2024-09-05	ホンジーンバイオテックコーポレイション	官能化ｎ－アセチルガラクトサミンアナログ
JP2024531728A (ja)	2021-09-14	2024-08-29	アルゴノートアールエヌエーリミテッド	心血管疾患の処置
EP4403633A1 (en) *	2021-09-18	2024-07-24	Genoval Therapeutics Co., Ltd.	Lpa inhibitor and use thereof
WO2023114746A1 (en)	2021-12-15	2023-06-22	Hongene Biotech Corporation	Functionalized n-acetylgalactosamine analogs
CN114703184B (zh) *	2022-03-11	2024-06-18	厦门甘宝利生物医药有限公司	Lpa抑制剂及其用途
WO2024032681A1 (zh) *	2022-08-11	2024-02-15	益杰立科(上海)生物科技有限公司	一种表观编辑靶点的方法及用途
CN115851723B (zh) *	2022-10-24	2023-10-03	厦门甘宝利生物医药有限公司	一种抑制lpa基因表达的rna抑制剂及其应用
WO2024118503A1 (en)	2022-11-28	2024-06-06	Hongene Biotech Corporation	Functionalized n-acetylgalactosamine analogs
WO2024151937A1 (en) *	2023-01-13	2024-07-18	Eli Lilly And Company	Therapeutic oligonucleotide-containing pharmaceutical compositions and dosing regimens using the same
CN118773191A (zh) *	2023-04-03	2024-10-15	翰森（上海）健康科技有限公司	靶向LPA基因的RNAi剂及其用途
WO2024222686A1 (zh) *	2023-04-24	2024-10-31	上海京新生物医药有限公司	用于抑制LPA表达的RNAi剂及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL9201440A (nl)	1992-08-11	1994-03-01	Univ Leiden	Triantennaire clusterglycosiden, hun bereiding en toepassing.
US5599706A (en)	1994-09-23	1997-02-04	Stinchcomb; Dan T.	Ribozymes targeted to apo(a) mRNA
ATE408699T1 (de)	1999-03-10	2008-10-15	Phogen Ltd	Verabreichung von nukleinsäuren und proteinen an zellen
US8137695B2 (en) *	2006-08-18	2012-03-20	Arrowhead Madison Inc.	Polyconjugates for in vivo delivery of polynucleotides
HU230458B1 (hu) *	2000-12-01	2016-07-28	Europäisches Laboratorium für Molekularbiologie (EMBL)	Az RNS interferenciát közvetítő kis RNS molekulák
US7227014B2 (en)	2001-08-07	2007-06-05	Isis Pharmaceuticals, Inc.	Antisense modulation of apolipoprotein (a) expression
US7259150B2 (en) *	2001-08-07	2007-08-21	Isis Pharmaceuticals, Inc.	Modulation of apolipoprotein (a) expression
JP2006523209A (ja)	2003-03-12	2006-10-12	アリゾナボードオブリージェンツオンビハーフオブザユニバーシティーオブアリゾナ	アペリン組成物によって血管新生を調節するための方法
AU2005222965B8 (en)	2004-03-15	2010-07-01	City Of Hope	Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
US20100249214A1 (en)	2009-02-11	2010-09-30	Dicerna Pharmaceuticals	Multiplex dicer substrate rna interference molecules having joining sequences
KR101728655B1 (ko)	2008-12-18	2017-04-19	다이서나 파마수이티컬, 인크.	유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
CN102869774B (zh)	2010-02-24	2018-02-09	箭头研究公司	用于靶向递送siRNA的组合物
US8865675B2 (en) *	2010-05-12	2014-10-21	Protiva Biotherapeutics, Inc.	Compositions and methods for silencing apolipoprotein B
CN103492568B (zh) *	2010-12-17	2017-04-12	箭头研究公司	用于siRNA的半乳糖簇‑药代动力学调节剂靶向部分
US8501930B2 (en)	2010-12-17	2013-08-06	Arrowhead Madison Inc.	Peptide-based in vivo siRNA delivery system
RU2619453C2 (ru)	2010-12-29	2017-05-16	Эрроухэд Фармасьютикалз, Инк.	КОНЪЮГАТЫ ДЛЯ ДОСТАВКИ ПОЛИНУКЛЕОТИДОВ in vivo, СОДЕРЖАЩИЕ ЧУВСТВИТЕЛЬНЫЕ К ФЕРМЕНТАТИВНОМУ РАСЩЕПЛЕНИЮ СВЯЗИ
CA2842039A1 (en)	2011-08-26	2013-03-07	Arrowhead Research Corporation	Poly(vinyl ester) polymers for in vivo nucleic acid delivery
CN108186667B (zh) *	2011-11-18	2021-07-20	阿尔尼拉姆医药品有限公司	RNAi试剂、组合物及其用于治疗甲状腺素运载蛋白（TTR）相关疾病的使用方法
AU2012377385A1 (en)	2012-04-18	2014-01-23	Arrowhead Research Corporation	Poly(acrylate) polymers for in vivo nucleic acid delivery
SI2855500T1 (sl) *	2012-05-24	2020-10-30	Ionis Pharmaceuticals, Inc.	Postopki in sestavki za moduliranje izražanja apolipoproteina(A)
CN105392488B (zh)	2013-05-01	2021-04-30	Ionis制药公司	用于调节载脂蛋白c-iii表达的组合物和方法
WO2016149020A1 (en) *	2015-03-17	2016-09-22	Arrowhead Research Corporation	Rna interference agents
EP3302503A4 (en)	2015-05-29	2019-08-07	Arrowhead Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR INHIBITING THE GENE EXPRESSION OF HIF2ALPHA
LT3329002T (lt) *	2015-07-31	2021-01-11	Alnylam Pharmaceuticals, Inc.	Transtiretino (ttr) irnr kompozicijos ir jų naudojimo būdai, skirti naudoti su ttr susijusių ligų gydymui arba prevencijai
UY37146A (es)	2016-03-07	2017-09-29	Arrowhead Pharmaceuticals Inc	Ligandos de direccionamiento para compuestos terapéuticos

2015
- 2015-10-01 JO JOP/2021/0043A patent/JOP20210043A1/ar unknown
2016
- 2016-09-28 JO JOP/2016/0211A patent/JOP20160211B1/ar active
- 2016-09-30 LT LTEPPCT/US2016/054729T patent/LT3356529T/lt unknown
- 2016-09-30 US US15/281,309 patent/US9932586B2/en active Active
- 2016-09-30 AU AU2016331084A patent/AU2016331084B2/en active Active
- 2016-09-30 EP EP21191363.7A patent/EP4029941A1/en active Pending
- 2016-09-30 RS RS20211351A patent/RS62523B1/sr unknown
- 2016-09-30 ES ES16852695T patent/ES2896298T3/es active Active
- 2016-09-30 HU HUE16852695A patent/HUE055942T2/hu unknown
- 2016-09-30 PL PL16852695T patent/PL3356529T3/pl unknown
- 2016-09-30 BR BR112018006489-0A patent/BR112018006489A2/pt active Search and Examination
- 2016-09-30 MY MYPI2018000440A patent/MY195796A/en unknown
- 2016-09-30 HR HRP20211410TT patent/HRP20211410T1/hr unknown
- 2016-09-30 JP JP2018516738A patent/JP6991966B2/ja active Active
- 2016-09-30 EP EP16852695.2A patent/EP3356529B1/en active Active
- 2016-09-30 TN TNP/2018/000094A patent/TN2018000094A1/en unknown
- 2016-09-30 SG SG10202008530TA patent/SG10202008530TA/en unknown
- 2016-09-30 EA EA201890864A patent/EA038478B1/ru unknown
- 2016-09-30 SI SI201631374T patent/SI3356529T1/sl unknown
- 2016-09-30 UA UAA201804593A patent/UA121998C2/uk unknown
- 2016-09-30 PE PE2018000487A patent/PE20181139A1/es unknown
- 2016-09-30 CA CA3000397A patent/CA3000397A1/en active Pending
- 2016-09-30 TW TW105131823A patent/TWI784934B/zh active
- 2016-09-30 UY UY0001036926A patent/UY36926A/es active IP Right Grant
- 2016-09-30 WO PCT/US2016/054729 patent/WO2017059223A2/en active Application Filing
- 2016-09-30 DK DK16852695.2T patent/DK3356529T3/da active
- 2016-09-30 CN CN201680057095.8A patent/CN108368506A/zh active Pending
- 2016-09-30 CR CR20180231A patent/CR20180231A/es unknown
- 2016-09-30 MX MX2018003833A patent/MX2018003833A/es unknown
- 2016-09-30 IL IL300438A patent/IL300438A/en unknown
- 2016-09-30 PT PT168526952T patent/PT3356529T/pt unknown
- 2016-09-30 TW TW111141660A patent/TWI836693B/zh active
2017
- 2017-04-06 MA MA43347A patent/MA43347B1/fr unknown
2018
- 2018-02-21 US US15/901,810 patent/US10662427B2/en active Active
- 2018-03-25 IL IL258333A patent/IL258333B/en unknown
- 2018-03-27 MX MX2022013010A patent/MX2022013010A/es unknown
- 2018-03-28 CL CL2018000803A patent/CL2018000803A1/es unknown
- 2018-03-28 PH PH12018500713A patent/PH12018500713A1/en unknown
- 2018-04-05 CO CONC2018/0003678A patent/CO2018003678A2/es unknown
2019
- 2019-01-29 HK HK19101563.4A patent/HK1259063A1/zh unknown
2020
- 2020-05-06 US US16/867,925 patent/US20200263179A1/en not_active Abandoned
2021
- 2021-03-12 JP JP2021039949A patent/JP7116212B2/ja active Active
- 2021-08-30 ZA ZA2021/06265A patent/ZA202106265B/en unknown
- 2021-11-08 CY CY20211100962T patent/CY1125263T1/el unknown
2022
- 2022-02-13 IL IL290566A patent/IL290566B2/en unknown
- 2022-06-15 JP JP2022096415A patent/JP7442574B2/ja active Active
- 2022-12-05 AU AU2022283623A patent/AU2022283623A1/en active Pending
2023
- 2023-11-27 JP JP2023199857A patent/JP2024009262A/ja active Pending

Also Published As

Publication number	Publication date
JP7442574B2 (ja)	2024-03-04
JP2021087459A (ja)	2021-06-10
AU2016331084A1 (en)	2018-04-19
AU2016331084B2 (en)	2022-09-08
PL3356529T3 (pl)	2021-12-20
IL290566B2 (en)	2023-07-01
CR20180231A (es)	2018-05-31
TW202332769A (zh)	2023-08-16
CY1125263T1 (el)	2023-03-24
US20170096665A1 (en)	2017-04-06
KR20180052703A (ko)	2018-05-18
PT3356529T (pt)	2021-11-04
WO2017059223A2 (en)	2017-04-06
MA43347B1 (fr)	2021-11-30
CO2018003678A2 (es)	2018-11-30
IL290566B1 (en)	2023-03-01
IL258333B (en)	2022-03-01
JP2024009262A (ja)	2024-01-19
EP3356529A2 (en)	2018-08-08
PE20181139A1 (es)	2018-07-17
TWI784934B (zh)	2022-12-01
IL300438A (en)	2023-04-01
JOP20210043A1 (ar)	2017-06-16
IL258333A (en)	2018-05-31
CA3000397A1 (en)	2017-04-06
JOP20160211B1 (ar)	2021-08-17
US20180195070A1 (en)	2018-07-12
MX2018003833A (es)	2018-06-18
NZ741086A (en)	2023-11-24
MX2022013010A (es)	2022-11-09
CL2018000803A1 (es)	2018-08-31
SG10202008530TA (en)	2020-10-29
TN2018000094A1 (en)	2019-07-08
ES2896298T3 (es)	2022-02-24
ZA202106265B (en)	2023-08-30
JP7116212B2 (ja)	2022-08-09
MY195796A (en)	2023-02-21
MA43347A (fr)	2018-08-08
EP3356529A4 (en)	2019-09-04
UA121998C2 (uk)	2020-08-25
CN108368506A (zh)	2018-08-03
BR112018006489A2 (pt)	2018-10-09
WO2017059223A3 (en)	2017-05-11
HK1259063A1 (zh)	2019-11-22
LT3356529T (lt)	2021-12-27
IL290566A (en)	2022-04-01
WO2017059223A9 (en)	2017-08-17
US20200263179A1 (en)	2020-08-20
JP6991966B2 (ja)	2022-02-03
UY36926A (es)	2017-04-28
PH12018500713A1 (en)	2018-10-15
US10662427B2 (en)	2020-05-26
AU2022283623A1 (en)	2023-02-02
TWI836693B (zh)	2024-03-21
JP2018529732A (ja)	2018-10-11
JP2022113835A (ja)	2022-08-04
EA201890864A1 (ru)	2018-09-28
EP4029941A1 (en)	2022-07-20
EA038478B1 (ru)	2021-09-03
SI3356529T1 (sl)	2022-01-31
HRP20211410T1 (hr)	2021-12-24
TW201726918A (zh)	2017-08-01
EP3356529B1 (en)	2021-08-25
HUE055942T2 (hu)	2022-01-28
RS62523B1 (sr)	2021-11-30
US9932586B2 (en)	2018-04-03

Publication	Publication Date	Title
DK3356529T3 (da)	2021-11-08	Sammensætninger og fremgangsmåder til hæmning af genekspression af lpa
DK3782639T3 (da)	2022-08-29	Sammensætninger og fremgangsmåder til internalisering af enzymer
DK3212778T3 (da)	2019-11-04	Fremgangsmåder og sammensætninger til stabilisering af trans-splejsning af intein-modificerede proteaser
DK3368541T3 (da)	2020-06-29	Sammensætninger og metoder til inhibiering af arginaseaktivitet
DK3390631T3 (da)	2020-07-13	Fremgangsmåder og sammensætninger til t-rna-baseret guide-rna-ekspression
DK3394030T3 (da)	2022-03-28	Forbindelser og sammensætninger til intracellulær afgivelse af midler
DK3307872T3 (da)	2023-10-23	Fremgangsmåder og sammensætninger til effektiv indgivelse af nukleinsyrer og rna-baserede antimikrober
DK3484469T3 (da)	2024-06-24	Sammensætninger og fremgangsmåder til potentiering af antimikrober
DK3137605T3 (da)	2020-12-14	Sammensætninger og fremgangsmåder til modulering af angiopoietin-lignende-3-ekspression
DK3134130T3 (da)	2019-08-26	Sammensætninger og fremgangsmåder til behandling af hæmoglobinopatier
DK3102673T3 (da)	2020-07-06	Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3495023T3 (da)	2020-07-20	Semifluorerede forbindelser og sammensætninger deraf
DK3119797T3 (da)	2021-03-15	Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose
DK3092256T3 (da)	2022-06-20	Forbindelser og sammensætninger til immunterapi
DK3628732T3 (da)	2023-05-30	Transposasesammensætninger til reduktion af insertionsbias
DK3144001T3 (da)	2021-11-15	Sammensætninger af selenoorganiske forbindelser og fremgangsmåder til anvendelse deraf
DK3393655T3 (da)	2021-03-15	Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3394272T5 (da)	2024-09-30	Sammensætninger og fremgangsmåder til effektiv målretning af transgener
DK3274430T3 (da)	2022-10-03	Mikroalgesammensætninger og deres anvendelser
DK3394259T3 (da)	2024-05-27	Sammensætninger og fremgangsmåder til reducering af tau-ekspression
DK3137596T3 (da)	2019-09-02	Sammensætninger og fremgangsmåder til modulation af komplement faktor b-ekspression
DK3143026T3 (da)	2024-09-30	Forbindelser og sammensætninger til induktion af chondrogenese
DK3200815T3 (da)	2021-05-10	Fremgangsmåder og sammensætninger til behandling af cancer
DK3110446T3 (da)	2022-02-28	Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme
DK3052628T3 (da)	2020-06-02	Sammensætninger og fremgangsmåder til inhibering af ekspression af alas1-genet